Efficacy and Safety of Levalbuterol Versus Racemic Albuterol in Asthma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00667407 |
Recruitment Status :
Completed
First Posted : April 28, 2008
Last Update Posted : February 22, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Asthma | Drug: Levalbuterol 1.25 mg Drug: Racemic Albuterol Sulfate | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 627 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-Blind Study to Determine the Efficacy of Levalbuterol Versus Racemic Albuterol in the Treatment of Acute Asthma |
Study Start Date : | November 2000 |
Actual Primary Completion Date : | August 2002 |
Actual Study Completion Date : | August 2002 |

Arm | Intervention/treatment |
---|---|
Experimental: 1
Levalbuterol 1.25 mg
|
Drug: Levalbuterol 1.25 mg
levalbuterol 1.25 mg Period I: administered every 20 minutes for the first 3 doses, and then every 40 minutes for the next 3 doses; then as clinically indicated. Period II: TID for 3 days (same time of day), then PRN to TID for 7 days Other Name: Xopenex HCl Inhalation Solution |
Active Comparator: 2
Racemic Albuterol 2.5 mg
|
Drug: Racemic Albuterol Sulfate
Racemic Albuterol 2.5 mg Period I: every 20 min for the first 3 doses, then every 40 min for the next 3 doses, then as clinically indicated. Period II: TID for 3 days then PRN to TID for 7 days Other Name: Ventolin Inhalation Solution |
- Time to meet discharge criteria (functional airway improvement)during the first 3 hours of Period I. [ Time Frame: 24 hours ]
- FEV1 (Period I): Serial spirometry, maximum FEV1, time to maximum FEV1, baseline FEV1 severity on subject response; % responders, no. nebulizations to meet discharge criteria, rate of hospitalization, time to admit decision, rate for increased care [ Time Frame: Day 0 (5-10 min after every dose) ]
- FEV1 (Period II): Spirometry, average FEV1; distribution of subject responses; rate of relapse; blinded study medication; length of stay in ED or Clinic during Period I; length of hospitalization, cost of care [ Time Frame: Days 3, 10 ]
- Investigator and subject global evaluations, subject preference [ Time Frame: Days 3, 10 ]
- Subject reported beta-mediated side effects [ Time Frame: Days 3, 10 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male and female subjects must be at least greater than or equal to 18 years of age at the time of consent.
- Subjects must have history of asthma for at least 6 months.
- Subjects must present to the emergency department (ED) or clinic with forced expiratory volume in one second (FEV1) of 20 to 55% (inclusive) predicted at baseline
- Subjects must have O2 saturation greater than or equal to 90% at room air or with no more than 6 Liters/minute supplemental oxygen and no other cause of wheezing or shortness of breath other than asthma as determined by the physician.
- Prior use of a beta-agonist (e.g., Primatine Mist, albuterol, salmeterol, etc.) within 24 hours of presentation to the ED or Clinic.
- Smoked ≤ 10 pack-years or non-smoker.
- Be in good health with the exception of asthma and not suffering from any chronic condition which might affect their lung function, such as COPD or emphysema.
- Near-normal activity level between exacerbations.
- Subjects who are taking inhaled or systemic corticosteroids must be on a stable dose for at least 21 days prior to study entry.
Exclusion Criteria:
- Subjects who have received treatment for asthma in an ED, Clinic, or Urgent Care Center within 2 weeks prior to study entry.
- Based upon history or physical exam in the ED or Clinic, subjects with known or suspected cause of pulmonary symptoms other than asthma, such as COPD, CHF, pneumonia, pulmonary embolism, or angioedema.
- Subjects with a history of asthma episodes associated with hypercapnia, respiratory arrest, hypoxic seizures, or requiring intubation within 12 months prior to entry.
- Hospitalization for asthma within two months prior to entry.
- Female subjects who are pregnant or lactating.
- Subjects who have a history of a clinically significant psychiatric disorder within the last 3 months, with the exception of mild depression.
- Subjects who have participated in an investigational drug study within 30 days of study entry or have previously participated in the current trial.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00667407
United States, Alabama | |
Hoover, Alabama, United States | |
Montgomery, Alabama, United States | |
United States, California | |
Encinitas, California, United States | |
Fresno, California, United States | |
Oakland, California, United States | |
Torrance, California, United States | |
United States, Colorado | |
Colorado Springs, Colorado, United States | |
United States, Florida | |
Gainesville, Florida, United States | |
Jacksonville, Florida, United States | |
Tampa, Florida, United States | |
United States, Illinois | |
Chicago, Illinois, United States | |
United States, Louisiana | |
Metairie, Louisiana, United States | |
United States, Michigan | |
Ann Arbor, Michigan, United States | |
Detroit, Michigan, United States | |
United States, Missouri | |
Kansas City, Missouri, United States | |
St. Louis, Missouri, United States | |
United States, New Jersey | |
Red Bank, New Jersey, United States | |
United States, New York | |
Brooklyn, New York, United States | |
New Hyde Park, New York, United States | |
Syracuse, New York, United States | |
United States, North Carolina | |
Rocky Mount, North Carolina, United States | |
United States, Ohio | |
Akron, Ohio, United States | |
Cleveland, Ohio, United States | |
United States, Oregon | |
Lake Oswego, Oregon, United States | |
Medford, Oregon, United States | |
United States, Pennsylvania | |
Philadelphia, Pennsylvania, United States | |
United States, Texas | |
Houston, Texas, United States | |
United States, Utah | |
Salt Lake City, Utah, United States |
Responsible Party: | Sunovion |
ClinicalTrials.gov Identifier: | NCT00667407 |
Other Study ID Numbers: |
051-915 |
First Posted: | April 28, 2008 Key Record Dates |
Last Update Posted: | February 22, 2012 |
Last Verified: | February 2012 |
Asthma |
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Pharmaceutical Solutions Albuterol Bronchodilator Agents Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Tocolytic Agents Reproductive Control Agents Adrenergic beta-2 Receptor Agonists Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |